**Core Concept**
Insulin analogues are modified forms of human insulin, designed to have a faster or slower onset and duration of action compared to regular human insulin. They are engineered to mimic the natural physiological insulin response more closely, providing improved glycemic control and flexibility in dosing.

**Why the Correct Answer is Right**
Insulin analogues typically have modifications in their amino acid sequence or chemical structure, which affect their binding to insulin receptors or their degradation rates. For example, insulin lispro (Humalog) has an amino acid substitution that allows it to be more rapidly absorbed and activated after injection. In contrast, the correct answer is not an insulin analogue because it does not possess these characteristic modifications.

**Why Each Wrong Option is Incorrect**
**Option A:** Insulin aspart (NovoLog) is an insulin analogue with a faster onset of action, making it suitable for mealtime dosing.
**Option B:** Insulin glargine (Lantus) is a long-acting insulin analogue that provides a flat, basal insulin profile throughout the day.
**Option C:** Insulin detemir (Levemir) is another long-acting insulin analogue with a modified fatty acid side chain that prolongs its duration of action.

**Clinical Pearl / High-Yield Fact**
When choosing between insulin analogues, consider the patient's lifestyle and dosing needs. For example, rapid-acting analogues like insulin aspart are ideal for mealtime dosing, while long-acting analogues like insulin glargine provide a more stable basal insulin profile.

**Correct Answer: D.**